Skip to main content
Figure 1 | Journal of Cardiothoracic Surgery

Figure 1

From: Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway

Figure 1

Sorafenib prevents the development of pressure overload-induced left ventricular hypertrophy (LVH) and cardiomyocyte volume. A. Following aortic banding (AB), LVH is anatomically evidenced by a significant rise in the ventricular weight to body weight (VW/BW) ratio (p < 0001, ***), which was blocked by sorafenib (p < 0001, ***). B. The observed LVH following AB is histologically accounted for by an increase in cardiomyocyte volume reflected by a significant increase in the cardiomyocyte cross-sectional area (CSA) expressed in μm2 (p < 0001, ***). This component of LVH was totally blocked by sorafenib treatment (p < 0.0001, ***). Cardiomyocyte CSA was measured in 10 different areas per section. Results were obtained from 2–4 sections per rat for a total of 6 rats selected at random from each group.

Back to article page

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us